tbuckley/cabot-search huggingface dataset:
Quantification of Serum HBsAg is a Useful Parameter to Optimize Antiviral NUC Therapy Schedule in Chronic Hepatitis B
Authors: M. Guarino, G. Portella, R. Bonavolta, F. Auriemma, V. Cossiga, R. Granata, L. Donnarumma, N. Caporaso, F. Morisco
Journal: Journal of Hepatology (2016)
A Prospective Study of t(4;14) Multiple Myeloma.
Authors: Lionel Karlin, David Ghez, Sylvain Choquet, Karim Belhadj, Margaret Macro, Didier Bouscary, Jean Soulier, Raphael Porcher, Marion Malphettes, Bouchra Asli, Jean-Claude Brouet, Jean-Paul Fermand, Bertrand Arnulf
Journal: Blood (2007)
Patients who Underwent Percutaneous Coronary Intervention Prior to Liver Transplantation Did Not Experience Bleeding Complications Whilst on Dual Antiplatelet Therapy
Authors: J.S. Nayagam, O. Raja, K. Agarwal, N. Heaton, M. Heneghan, J. O’Grady, A. Suddle, V. Aluvihare
Journal: Journal of Hepatology (2016)
The Baveno VI Guidelines: Can We Confidently Identify Low Risk Cirrhotic Patients not Requiring Endoscopic Surveillance for Varices?
Authors: J.B. Maurice, E. Brodkin, F. Arnold, H. Paine, A.M.D. Navaratnam, S. Khawar, E. Tsochatzis, D. Patch, J. O’Beirne, A. Dhar, M. Pinzani, R.H. Westbrook
Journal: Journal of Hepatology (2016)
Genetic and Metabolic Factors Related with Insulin Resistance in Chronic Hepatitis C
Authors: B. Mateos-Muñoz, E. García-Martin, M.J Torrejón, M.J. Devesa-Medina, G. Esguevillas, M.C. Cárdenas, C. Fernandez, M. Carballo, J.A. Agundez, J.M. Ladero
Journal: Journal of Hepatology (2016)
Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy.
Authors: A. Hendlisz, V. Golfinopoulos, C. Garcia, P. Emonts, A. Covas, L. Ameye, M. Paesmans, A. Deleporte, G. Machiels, E. Toussaint, B. Vanderlinden, A. Awada, M. Piccart, P. Flamen
Journal: Journal of Clinical Oncology (2011)

3593 Background: The purpose of our study was to assess the predictive value of FDG-PET/CT metabolic response after a single course of chemotherapy in patients with metastatic colorectal cancer (mCRC). Methods: We performed two FDG-PET/CT scans (at baseline and on day 14) in 41 patients with unresectable mCRC treated with a biweekly regimen of chemotherapy. Patients were classified as metabolically non-responders when the dominant proportion of the tumor load showed a decrease in FDG uptake less than 15%, or if at least one lesion was demonstrated to be metabolically progressive. The PET-based response was correlated with RECIST-based response (primary endpoint), and progression-free and overall survival (secondary endpoints). Results: RECIST response rate in metabolically responding patients was 43% (10/23) compared to 0% (0/17) in metabolically non-responding patients (P=0.002). The predictive performance of the metabolic assessment for RECIST response was sensitivity 100% (95% CI, 69% to 100%), specificity 57% (95% CI, 37% to 75%), positive predictive value 43% (95% CI, 23% to 66%) and negative predictive value 100% (95% CI, 80% to 100%). Comparing metabolically responding versus non-responding patients, the hazard ratio was 0.28 (95% CI, 0.10 to 0.76, P=0.008) for overall survival and 0.57 (95% CI, 0.27 to 1.21, P=0.14) for progression-free survival. Conclusions: The metabolic response measured by FDG-PET/CT after a single course of chemotherapy in mCRC is able to identify the patients who will not benefit from the treatment.
A Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir in Non-Cirrhotic Adult Asians with HCV Genotype 1B
Authors: J. Heo, L. Wei, Y. Luo, W.-L. Chuang, L. Fredrick, K. Alves, R. Redman, A. Campbell, N. Mobashery
Journal: Journal of Hepatology (2016)
Innate Immune Sensing of Hepatitis B Virus and Response to Interferon Stimulation are Mostly Elicited in Non HBV Producing Human Hepatocytes in Vivo
Authors: L. Allweiss, J. Bockmann, T. Volz, K. Giersch, J. Kah, A.W. Lohse, J. Petersen, M. Lütgehetmann, M. Dandri
Journal: Journal of Hepatology (2016)
Virologic Response following Asunaprevir/Daclatasvir with or without Beclabuvir for Treatment of HCV Genotype 1 in Patients Co-Infected with HIV
Authors: E.S. Rosenthal, L. Howard, J. Purdy, M. McLaughlin, S. Kattakuzhy, A. Kohli, E. Wilson, H. Masur, S. Kottilil
Journal: Journal of Hepatology (2016)
Serum IL-12:IL-6 Ratio Reliably Distinguishes Infectious from Non-Infectious Causes of Fever during Autologous Stem Cell Transplantation (ASCT).
Authors: Tarun Kewalramani, Roman A. Tuma, Nikolaos G. Almyroudis, Sejean Sohn, Robert D. Rice, David Galinkin, Melissa Blain, Jing Qin, Eric G. Pamer, Stephen D. Nimer
Journal: Blood (2004)
Lung structure and function in cigarette smokers.
Authors: W M Thurlbeck
Journal: Thorax (1994)

Lung structure and function in cigarette smokersIn their paper (May 1994;49:473-8) Dr Hogg and colleagues are to be congratulated on the size of their lung collection from which they conclude that neither lesions in the bron- chioles nor emphysema are related to the forced expiratory volume in the first second as a percentage of predicted (FEV1%).This is so at variance with the large body of lit- erature that has accumulated over the past 30 years that their data require critical ex- amination.
Acupuncture for Menopausal Hot Flashes
Authors: John Varner
Journal: Annals of Internal Medicine (2016)

Letters20 September 2016Acupuncture for Menopausal Hot FlashesJohn Varner, LAcJohn Varner, LAcFrom Baystate Hospital Pain Management Center, Springfield, Massachusetts.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L16-0198 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Ee and colleagues' claim that acupuncture is not superior to “placebo” acupuncture (1) is misleading. I am an acupuncturist and participated in a placebo acupuncture trial of acupuncture treatment of perimenopausal symptoms in women receiving estrogen suppressors. Participants kept journal records of their experiences, noting changes in the number and intensity of HFs, sleep patterns, and general well-being. The trial concluded that some participants benefited from the placebo acupuncture procedure, which was actually similar to a common Japanese style of acupuncture, whereas others benefited from the “real” acupuncture treatment, which was a hobbled version of traditional Chinese-style ...Reference1. Ee C, Xue C, Chondros P, Myers SP, French SD, Teede H, et al. Acupuncture for menopausal hot flashes: a randomized trial. Ann Intern Med. 2016;164:146-54. [PMID: 26784863]. doi:10.7326/M15-1380 LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Baystate Hospital Pain Management Center, Springfield, Massachusetts.Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterest Forms.do?msNum=L16-0198. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoAcupuncture for Menopausal Hot Flashes Carolyn Ee , Charlie Xue , Patty Chondros , Stephen P. Myers , Simon D. French , Helena Teede , and Marie Pirotta Acupuncture for Menopausal Hot Flashes Nobuari Takakura , Miho Takayama , and Hiroyoshi Yajima Acupuncture for Menopausal Hot Flashes Ana Maria Lopez , Angela Presson , Annie Budhathoki , and Shelley White Acupuncture for Menopausal Hot Flashes Carolyn Ee , Charlie Xue , and Marie Pirotta Metrics 20 September 2016Volume 165, Issue 6Page: 450KeywordsAcupunctureAnxietyBlood vesselsConflicts of interestDisclosureEstrogensHormonesNervous systemSleep ePublished: 20 September 2016 Issue Published: 20 September 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Individualized surveillance and follow-up based on breast cancer (BC) subtypes and risk of relapse in BC patients who received curative surgery.
Authors: S. Lee, Y. Park, J. Sun, J. Seo, J. Lee, S. Nam, J. Yang, J. Ahn, Y. Im
Journal: Journal of Clinical Oncology (2010)

e11053 Background: Gene expression profiles using DNA microarrays have shown at least 5 distinct breast cancer (BC) subtypes. According to these subtypes, clinical features can vary in relapse patterns, preferential metastatic sites, and the risk of systemic failures. However, the surveillance programs which have been developed to date are uniformly designed, and do not reflect the differences among subtypes. The purpose of this study was to evaluate the need for an individualized surveillance and follow-up based on subtypes and risk of relapse in BC patients after curative surgery. Methods: We retrospectively analyzed the clinicopathologic characteristics and outcomes of patients with invasive BC who received curative surgery between 2000 and 2004 at the Samsung Medical Center. Results: Among 1,879 patients who underwent BC surgery, 316 (17%) showed signs of relapse during a median follow-up of 75 months. HER2 positivity (HR, 2.3; p < 0.0001), triple negativity (HR, 1.6; p = 0.007), high histological grade (HG) (HR, 1.6; p = 0.001), and TNM stage 3 (HR, 3.7; p < 0.0001) were identified as independent risk factors for prediction of relapse. We used scoring system by these risk factors as follows: score 0, no risk factors; score 1, 1 risk factor; score 2, 2 risk factors; and score 3, 3 risk factors. Patients with a score of 0-2 were identified as being at low risk and those with a score 3 at high risk for relapse. This high-risk group was composed of two subsets: (1) HER2 positive BC with a high HG and TNM stage 3 and (2) triple negative BC with a high HG and TNM stage 3. The relapse rates of low- and high-risk group were 16% and 53%, respectively. The distant relapse rates for both groups were 12% and 51%. The median relapse-free survival for high-risk patients were 49 months whereas not reached for low risk (p < 0.0001). Most instances of relapse occurred within 3 years of surgery for high-risk patients. The 5-year survival rate of the high-risk patients was 65% compared to 96% for low- risk. Conclusions: Our study showed that there is a need to implement an individualized surveillance based on subtypes and risk of relapse for postoperative surveillance and it should be focused more on patients with a high risk of relapse. No significant financial relationships to disclose.
P1.05: An International Epidemiological Analysis of Young Patients Diagnosed With NSCLC (ADUJOV-CLICaP)
Authors: Luis Corrales-Rodriguez, Oscar Arrieta, Luis Mas, Omar O. Castillo-Fernandez, Normand Blais, Claudio Martin, Ludwing Bacon, Allan Ramos-Esquivel, Mauricio Cuello, Leonardo Rojas, Melissa Juárez, Andrés F. Cardona
Journal: Journal of Thoracic Oncology (2016)
Progressive Alterations in Systemic and Cardiopulmonary Hemodynamics Occur in Patients with Cirrhosis and Predict Death in Decompensated Cirrhosis
Authors: L. Turco, G. Garcia-Tsao, I. Magnani, M. Bianchini, M. Costetti, R. Rossi, E. Villa, F. Schepis
Journal: Journal of Hepatology (2016)
Study Of Stem Cell Homing and Donor-Recipient Cellular Interaction In Allogenic Hematopoietic Stem Cell Transplantation Mice Model
Authors: Qianli Jiang, Yan-yan Ye, Le-zhong Yuan, Shan Jiang, Jing Sun, Pei-ran Zhao, Chang-xin Yin, Qing Mai, Kefeng Shen, Hao Huang, Yang Lu, Fanyi Meng, Qi-Fa Liu
Journal: Blood (2013)
Sofosbuvir-Based-Regimen for HCV Recurrence after Combined Liver-Kidney Transplantation : Results from the ANRS CO23 Cupilt Study
Authors: S. Dharancy, A. Coilly, C. Fougerou-Leurent, C. Duvoux, N. Kamar, V. Leroy, A. Tran, P. Houssel-Debry, V. Canva, C. Moreno, F. Conti, J. Dumortier, V. Di Martino, S. Radenne, V. De Ledinghen, L. D’Alteroche, C. Silvain, C. Besch, P. Perré, D. Botta-Fridlund, C. Francoz, F. Habersetzer, H. Montialoux, A. Abergel, M. Debette-Gratien, A. Rohel, J.C.D. Vallée, G.-P. Pageaux
Journal: Journal of Hepatology (2016)
Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R cHL): phase 2 KEYNOTE-087 study.
Authors: Robert W. Chen, Pier Luigi Zinzani, Michelle A. Fanale, Philippe Armand, Nathalie Johnson, Vincent Ribrag, John A. Radford, Akihiro Tomita, Margaret Ann Shipp, Yang Wang, Alejandro Daniel Ricart, Arun Balakumaran, Craig H. Moskowitz
Journal: Journal of Clinical Oncology (2016)

7555 Background: Patients (pts) with cHL who relapse after autologous stem-cell transplant (ASCT) or progress after brentuximab vedotin (BV) have a poor prognosis. The PD-1 ligands PD-L1 and PD-L2 are frequently overexpressed in R/R cHL. Pembrolizumab is a humanized monoclonal antibody against PD-1 preventing binding to PD-L1 and PD-L2. In the phase 1b KEYNOTE-013 study, pembrolizumab demonstrated high antitumor activity (ORR = 65%) in heavily pretreated cHL pts. KEYNOTE-087 (NCT02453594) is a multicohort phase 2 study designed to confirm clinical activity of pembrolizumab in cHL pts. Methods: The study has 3 cohorts: R/R cHL after ASCT and subsequent BV therapy (cohort 1); ineligible for ASCT due to chemo-resistance (no response to salvage chemotherapy) and BV therapy failure (cohort 2); R/R cHL after ASCT but not treated with BV after ASCT (cohort 3). Pts receive pembrolizumab at a fixed dose of 200 mg IV Q3W. Primary end point is ORR, with response assessed every 12 wk according to Revised Response Criteria for Malignant Lymphomas. Prespecified interim analysis, based on investigator-assessed response, was performed after 30 pts reached first response assessment in cohorts 1 and 2. Results: At time of data cutoff (Feb 1, 2016), 60 pts were evaluable for cohorts 1 and 2. Median (range) age was 36 (19-64) years in cohort 1 and 33 (20-71) in cohort 2. 67% received ≥ 4 prior lines of therapy, and by design 100% failed prior BV. ORR among 30 pts in cohort 1 is 70% (95% CI, 51-85). 6 pts (20%) achieved CR (residual mass permitted if PET negative), 15 (50%) PR, and 6 (20%) stable disease as best response. ORR among 30 pts in cohort 2 is 80% (95% CI, 61-92). 8 pts (27%) achieved CR, 16 (53%) PR, and 4 (13%) stable disease as best response. With a median of 6 treatment cycles, most common treatment-related AEs in the combined cohorts are pyrexia (13%), diarrhea (8%), fatigue, back pain, platelet count decrease, dry skin, and cough (7% each). Conclusions: PD-1 blockade with pembrolizumab shows early responses in heavily pretreated cHL pts. Of note, pembrolizumab shows an unprecedented high ORR (80%) in pts who were not candidates for ASCT and failed previous BV therapy. Cohort 3 continues accrual and interim analysis results will be presented. Clinical trial information: NCT02453594.
Busulfan (Bu) Plus Cyclophosphamide (Cy) Versus TBI Plus Cy Conditioning for Allogeneic Stem Cell Transplantation (alloSCT) From Matched Unrelated Donors (MUD) In Adult Patients with AML in First Relapse: A Survey From the Acute Leukemia Working Party of EBMT
Authors: Arnon Nagler, Myriam Labopin, Avichai Shimoni, Jürgen Finke, Dietrich Beelen, Liisa Volin, Jakob R. Passweg, Rainer Schwerdtfeger, Hans-Jochem Kolb, Achilles Anagnostopoulos, Vanderson Rocha, Fabio Ciceri, Mohamad Mohty
Journal: Blood (2011)
Oxaliplatin in combination with 5-fluorouracil (FU) in a 48-hour continuous infusion (CI) as first-line chemotherapy for elderly patients (pts) with metastatic colorectal cancer (mCRC). TTD phase II trial
Authors: C. Pericay, M. Valladares, M. Benavides, B. Massutí, J. Aparicio, R. Dueñas, E. González-Flores, A. Carrato, E. Marcuello, E. Aranda
Journal: Journal of Clinical Oncology (2008)

4057 Background: We previously reported a 35% overall response rate (ORR) with 5-FU CI (TTD schedule without modulation) plus CPT-11 as first line therapy in elderly pts with mCRC (Sastre et al. J Clin Oncol 23; 3545–51, 2005). The present study was carried out also in elderly pts to determine the efficacy (ORR as primary endpoint) and safety of oxaliplatin in combination with the same 5-FU schedule. Methods: Pts >72 y. with histologically confirmed mCRC, measurable disease, ECOG < 0–2, no previous adjuvant oxaliplatin and no prior treatment for metastatic disease. Treatment: Oxaliplatin 85 mg/m2 plus 5-FU 3,000 mg/m2 as a 48-hour CI q2w until progressive disease, undesirable toxicity or consent withdrawal. Results: 134 pts were included and 129 (96%) were eligible. Median age: 76y (72–85), male/female: 63/37%, and ECOG 0/1/2: 42/53/5%. Main comorbidities were hypertension (44%), diabetes (17%) and EPOC (11%). Median No of metastatic locations was 1 (37% with > 2 sites) mainly located in liver (77%) and lung (29%). 21% of pts received previous adjuvant chemotherapy. Efficacy: On an ITT analysis of 129 pts, ORR and control disease (ORR+SD) were 52% and 80% respectively. With a median follow-up of 14 months, median progression free survival and overall survival were 9 and 16.2 months respectively. 48 pts (37%) received 2 or more lines of chemotherapy mainly based in CPT-11. Seven pts (5.4%) followed resection of liver metastasis, of which 5 were complete. Grades 3–4 toxicities included anemia (2%), asthenia (9%), neutropenia (17%), febrile neutropenia (2%), thrombocytopenia (5%), diarrhoea (11%), nausea/vomiting (5/4%) and neurotoxicity grade 3 (18%). There was one treatment related death (pneumonia). Conclusion: To our knowledge this is the largest phase II prospective study in elderly pts with mCRC. The schedule seems to be effective and compared favourably with those reported in the literature in this population. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration sanofi-aventis
Effects of Oral High-Dose Vitamin D Supplementation on Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: A Randomised, Double-Blind, Placebo-controlled Trial
Authors: I. Barchetta, F. Angelico, M. Del Ben, M. Di Martino, A. Fraioli, G. La Torre, S. Morini, C. Tiberti, R. Del Vescovo, L. Bertoccini, F.A. Cimini, C. Catalano, M.G. Baroni, M.G. Cavallo
Journal: Journal of Hepatology (2016)
Multimodal population brain imaging in the UK Biobank prospective epidemiological study
Authors: Karla L Miller, Fidel Alfaro-Almagro, Neal K Bangerter, David L Thomas, Essa Yacoub, Junqian Xu, Andreas J Bartsch, Saad Jbabdi, Stamatios N Sotiropoulos, Jesper L R Andersson, Ludovica Griffanti, Gwenaëlle Douaud, Thomas W Okell, Peter Weale, Iulius Dragonu, Steve Garratt, Sarah Hudson, Rory Collins, Mark Jenkinson, Paul M Matthews, Stephen M Smith
Journal: Nature Neuroscience (2016)
Phase I dose-escalation study of the protein kinase C (PKC) inhibitor AEB071 in patients with metastatic uveal melanoma.
Authors: Sophie Piperno-Neumann, Ellen Kapiteijn, James M. G. Larkin, Richard D. Carvajal, Jason J. Luke, Heike Seifert, Inge Roozen, Mustapha Zoubir, Lin Yang, Somesh Choudhury, Padmaja Yerramilli-Rao, F. Stephen Hodi, Gary K. Schwartz
Journal: Journal of Clinical Oncology (2014)

9030 Background: Uveal melanoma is characterized by frequent mutations in GNAQ or GNA11 that encode for G-protein α-subunits (Gα) which mediate signaling from G-protein coupled receptors to downstream signaling pathways, including PKC. AEB071 (sotrastaurin) is a potent, selective oral inhibitor of the classical (α, β), and novel (δ, ε, η, θ) isoforms of PKC. Preclinical data shows selective sensitivity of Gα mutant uveal melanoma cell lines to AEB071. Methods: An open-label, multicenter, single-arm, Phase I study was performed in pts (WHO performance status [PS] ≤1) with metastatic uveal melanoma. Dose escalation and estimation of the maximum tolerated dose (MTD) was guided by an adaptive Bayesian logistic regression model with overdose control. Results: 118 pts received AEB071 at total daily doses of 450−1400 mg administered in divided doses either BID or TID. Genomic profiling analysis has been completed in 52 pts, 96% of which were found to have activating mutations in either GNAQ or GNA11. Dose-limiting toxicities (DLTs) were observed in 12 pts (11%) at doses ≥800 mg/day total (nausea [7%], vomiting [2%], and fatigue [2%]). The MTD was 800 mg/day and 1400 mg/day on TID and BID dosing schedules, respectively. The most common AEB071-related adverse events (AEs) (all grades, all cohorts, >25%) were nausea (68%), dysgeusia (58%), constipation (48%), vomiting (42%), diarrhea (36%), chromaturia (35%), and asthenia (26%). AEB071 exposure increased with increasing dose and was approximately 1–2x higher at steady state during BID dosing, with a median Tmax of 1–4 hr. Decreases in the PKC substrate phosphorylated myristoylated alanine-rich C kinase substrate (pMARCKS) of approximately 40%–90% were seen by Cycle 1 Day 15 for both dosing regimens. pMARCKS suppression did not correlate with clinical response or time on study. One pt achieved a PR and 55/118 (47%) pts achieved SD and progression-free survival (PFS) ranging from <1–57 weeks and with a median PFS of 15.4 weeks (95% CI 8.3–15.7). Conclusions: Preliminary data suggest clinical activity of AEB071 and manageable toxicity at multiple dose levels, with evidence of PKC inhibition in patients with uveal melanoma. Clinical trial information: NCT01430416.
High Rates of Hepatitis B Virus (HBV) Flare and Reactivation among Patients with Chronic Inactive HBV and Prior Resolved HBV Infection Treated with Rituximab
Authors: K. Junus, M. Aguilar, P. Patel, D. Irwin, S. Yee, B. Liu, T. Bhuket, R. Wong
Journal: Journal of Hepatology (2016)
Circulating CD36 Correlates with Intrahepatic Lipid Content in Non-Alcoholic Fatty Liver Disease Patients
Authors: S. Heebøll, M.K. Poulsen, M.J. Ørnstrup, T.N. Kjær, S.B. Pedersen, S. Nielsen, A. Handberg, H. Grønbæk
Journal: Journal of Hepatology (2016)
Favorable Outcomes following Tips in Idiopathic Non-Cirrhotic Portal Hypertension with Variceal Bleeding: A Case-Control Study from a Single Center
Authors: B. Zhang, Y. Lv, X. Meng, W. Guo, B. Luo, Z. Wang, C. He, Z. Yin, J. Wang, S. Ren, J. Cai, J. Niu, D. Fan, Z. Li, G. Han
Journal: Journal of Hepatology (2016)